IDiyas

For the Inventor, By the Inventor

Ardsley, NY, United States of America

Acorda Therapeutics, Inc.


USPTO Granted Patents = 90



Trademarks = 55

Forward Citations = 348

Loading Chart...
Loading Chart...

99 inventors (with patents filed for the assignee):

goldMedal Anthony O Caggiano (36 out of 36 patents)

silverMedal Jennifer Iaci (23 out of 23 patents)

bronzeMedal Andrea M Vecchione (16 out of 16 patents)

4.  Mark Andrew Marchionni (16 out of 24 patents)

5.  Keith R Bley (15 out of 25 patents)

6.  Elliott A Gruskin (14 out of 41 patents)

7.  Naweed Muhammad (14 out of 24 patents)

8.  Gargi Roy (8 out of 8 patents)

9.  Andrew David Goodearl (8 out of 20 patents)

10.  Luisa Minghetti (8 out of 19 patents)

11.  Paul Stroobant (8 out of 20 patents)

12.  Michael Derek Waterfield (8 out of 31 patents)

13.  Ian D Hiles (8 out of 24 patents)

14.  Andrew R Blight (6 out of 6 patents)

15.  Ron Cohen (6 out of 6 patents)


Core Competencies:
Sustained Release Compositions
Neuregulin Therapeutic Dosing
Inflammatory Cell Extravasation
Cardiac Damage Detection
Water-Soluble Acetaminophen
CNS Neurological Injury Treatment
Chondroitinase ABCI Mutants
Dopaminergic Neuron Protection
Neuronal Outgrowth Promotion
Hepatoprotectant Prodrugs
TRPV1 Agonist Administration
Fusion Proteins for CNS

90 patents:

1. 12029820 - Sustained release compositions of 4-aminopyridine (2024-07-09),
2. 11235031 - Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure (2022-02-01),
3. 11141467 - Methods of reducing extravasation of inflammatory cells (2021-10-12),
4. 11136342 - Carbonate prodrugs and methods of using the same (2021-10-05),
5. 11071770 - Methods for detecting cardiac damage (2021-07-27),
6. 11021498 - Water-soluble acetaminophen analogs (2021-06-01),
7. 10717775 - Methods for cardiomyocyte survival, proliferation or differentiation by NRG-2 (2020-07-21),
8. 10675331 - Method for achieving desired glial growth factor 2 plasma levels (2020-06-09),
9. 10668131 - Compositions and methods for treatment during non-acute periods following CNS neurological injury (2020-06-02),
10. 10442826 - Water-soluble acetaminophen analogs (2019-10-15),
11. 10377779 - Carbonate prodrugs and methods of using the same (2019-08-13),
12. 10323240 - Compositions and methods of using chondroitinase ABCI mutants (2019-06-18),
13. 10258667 - Methods for detecting cardiac damage (2019-04-16),
14. 10232016 - Methods for treating congestive heart failure (2019-03-19),
15. 10065999 - Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by NRG-2 (2018-09-04),
Acorda Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for people with neurological disorders. With a focus on Parkinson's disease, Acorda delivers treatments that improve patients' lives and advance research in the field. Their website provides comprehensive information about their product portfolio, clinical trials, and corporate news.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
90 Patents

#2 in Ardsley, NY

#229 in New York

#3,997 in US

#8,250 in the World

...
Ardsley, NY, United States of America

Acorda Therapeutics, Inc.

Forward Citations = 348

99 inventors:

goldMedal Anthony O Caggiano (36 out of 36 patents)

silverMedal Jennifer Iaci (23 out of 23 patents)

bronzeMedal Andrea M Vecchione (16 out of 16 patents)

4.  Mark Andrew Marchionni (16 out of 24 patents)

5.  Keith R Bley (15 out of 25 patents)

Please report any incorrect information to support@idiyas.com
Loading…